BLP-25 liposomal vaccine: a promising potential therapy in nonsmall-cell lung cancer

Abstract

Despite marginal improvements in survival gained from multimodality treatment, long-term survival rates remain low for lung cancer, which remains the leading cause of cancer-related mortality in North America. BLP25 liposomal (L-BLP25) vaccine (Stimuvax) is a promising liposomal vaccine designed to generate an immune response against MUC1, a glycoprotein expressed on the cell surface of many normal epithelial tissues and over or aberrantly expressed on many carcinoma cells, including non-small-cell lung cancer (NSCLC). MUC1 is potentially a good target for immunotherapy, as evidenced by preclinical data and in Phase I and II clinical trials demonstrating the potential early activity of L-BLP25 with minimal toxicity in NSCLC. A Phase III randomized, placebo-controlled trial of L-BLP25 is currently being conducted in stage III NSCLC patients.